Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia - Cheong, Sok Ching; Selvam, Bawani; Ho, Gwo Fuang; Muhamad Nor, Ibtisam; Tan, Chih Kiang; Wong, Yoke Fui; Teo, Soo Hwang; Lim, Kue Peng; Chai, Annie Wai Yeeng; Yahya, Abqariyah; Wan Ishak, Wan Zamaniah (BMJ open, 2024)
Keywords: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asian people; Biomarkers; Biomedical research; Cancer; CHEMOTHERAPY; Cisplatin - administration & dosage; Cisplatin - therapeutic use; Clinical trials; Clinical Trials, Phase II as Topic; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Female; Gemcitabine; Head & neck cancer; Head & neck tumours; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - pathology; Humans; IMMUNOLOGY; Immunotherapy; Informed consent; Malaysia; Male; Metastasis; Middle Aged; Monoclonal antibodies; Multicenter Studies as Topic; Neoplasm Recurrence, Local - drug therapy; Oncology; Patient safety; Pregnancy; Protocol; Response rates; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - drug therapy; Targeted cancer therapy; Throat cancer; Toxicity; Malaysia; CHEMOTHERAPY; Head & neck tumours; IMMUNOLOGY